Table 2 Baseline demographic and clinical features of 200 chronic hepatitis C patients with interferon-alpha therapy
Total | 3-MU group† No. (%) | 6-MU group‡ No. (%) | |
|---|---|---|---|
Patient Number | 200 | 76 | 124 |
Gender | |||
Male | 103 | 34(44.7) | 69(55.6) |
Female | 97 | 42(55.3) | 55(44.4) |
Age (year) | 47.3 ± 10.4 | 45.3 ± 11.7 | |
History of transfusion | |||
No | 141 | 56(73.7) | 85(68.5) |
Yes | 59 | 20(26.3) | 39(31.5) |
Liver histopathology | |||
Total score of necroinflammatory activity | 4.48 ± 2.56 | 4.23 ± 2.46 | |
Fibrosis score | |||
F3–4 | 70 | 30(39.5) | 40(32.3) |
F0–2 | 130 | 46(60.5) | 84(67.7) |
Pretreatment ALT value (U/L) | 117.4 ± 102.8 | 104.1 ± 95.4 | |
Pretreatment HCV RNA level (log equivalent/mL) | 5.97 ± 0.59 | 6.01 ± 0.68 | |
HCV genotype | |||
1b | 80 | 27(35.5) | 53(42.7) |
Non-1b | 120 | 49(64.5) | 71(57.3) |
Interferon preparation | |||
Recombinant IFN-α-2a | 37 | 10(13.2) | 27(21.8) |
Recombinant IFN-α-2b | 95 | 36(47.4) | 59(47.6) |
Lymphoblastoid IFN-α-n1 | 68 | 30(39.5) | 38(30.6) |